NCIC Clinical Trials Group ASCO Annual Meeting Presentations

Transcription

1 Saturday, June 1 Session Title: Central Nervous System Tumors IND Poster Board: #3A Phase II study of PX-866 in recurrent glioblastoma. (Abstract #2053) Marshall W. Pitz, MD FRCPC Session Title: Lung Cancer - Non-small Cell Metastatic BR.24 - Poster Board: #33D Exploratory analysis of angiotensin converting enzyme (ACE) and aldosterone (Ald) serum levels as prognostic and predictive biomarkers on the NCIC CTG BR24 trial. (Abstract #8048) Jair Bar, MD, PhD Session Title: Breast Cancer - HER2/ER Location: E450b Time: 8:00 AM - 12:00 PM Chair and/or Co-Chairs: Stephen R. Johnston, MA, MD, PhD, and Tufia C. Haddad, MD IND Poster Board: #6 A phase Ib study of an anti-her2 inhibitor, lapatinib, in combination with a c-met and VEGFR inhibitor, foretinib, in HER2-positive metastatic breast cancer (MBC): Results from NCIC CTG IND.198. (Abstract #518) Stephen K. Chia, MD

2 Session Title: Breast Cancer - HER2/ER Time: 1:15 PM - 5:00 PM MA.27 - Poster Board: #4C Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus anastrozole. (Abstract #564) Judy-Anne W. Chapman, PhD Session Title: Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers Location: E450b Time: 1:15 PM - 5:15 PM Chair and/or Co-Chairs: Christine L. Hann, MD, PhD, and Roy H. Decker, MD, PhD IND Poster Board: #4 Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES- SCLC): An Alliance-led analysis. (Abstract #7510) Nathan R. Foster, MS Session Title: Gynecologic Cancer Location: E354b Time: 3:00 PM - 6:00 PM Chair and/or Co-Chairs: Paul Haluska, MD, PhD, and Gini F. Fleming, MD OV.16-3:30 PM - 3:45 PM Final results of OV16, a phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel (CP) versus CP in first-line chemotherapy for advanced epithelial ovarian cancer (EOC): A GCIG study of NCIC CTG, EORTC-GCG, and GEICO. (Abstract #5502) Andres Cervantes-Ruiperez, MD

3 Session Title: Central Nervous System Tumors Location: E253 Time: 3:00 PM - 6:00 PM Chair and/or Co-Chairs: Howard A. Fine, MD, and Mark R. Gilbert, MD CE.5-5:15 PM - 5:30 PM Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss) low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC- CTG/TROG/MRC-CTU (EORTC ). (Abstract #2007) Brigitta G. Baumert, MD, PhD, MBA Sunday, June 2 Session Title: Patient and Survivor Care Date: Sun, Jun 2 Location: S100a Time: 8:00 AM - 11:00 AM Chair and/or Co-Chairs: Tara O. Henderson, MD, MPH SC.20-8:30 AM - 8:45 AM A randomized trial of single versus multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20. (Abstract #9502) Edward Chow, MBBS PhD Session Title: Gastrointestinal (Colorectal) Cancer Date: Sun, Jun 2 CO.21 - Poster Board: #15A A phase III study of the impact of a physical activity program on disease-free survival in patients with high-risk stage II or stage III colon cancer: A randomized controlled trial (NCIC CTG CO.21). (Abstract #TPS3647) Christopher M. Booth, MD

4 Session Title: Gastrointestinal (Noncolorectal) Cancer Date: Sun, Jun 2 PA.3 - Poster Board: #18G Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial. (Abstract #4061) Daniel J. Renouf, MD PA.3 - Poster Board: #17G Significance of baseline quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. (Abstract #4053) Michael M. Vickers, MD, FRCPC Monday, June 3 Session Title: Genitourinary (Prostate) Cancer IND Poster Board: #36A NCIC CTG, IND-205: A phase II study of PX-866 in patients with recurrent or metastatic castration resistant prostate cancer (CRPC). (Abstract #5042) Sebastien J. Hotte, MD, MSc Session Title: Melanoma/Skin Cancers Location: S405 Time: 8:00 AM - 12:00 PM Chair and/or Co-Chairs: Kevin Kim, MD, and Ryan J. Sullivan, MD IND Poster Board: #20 Final efficacy results of NCIC CTG IND.202: A randomized phase II study of recombinant interleukin-21 (ril21) in patients with recurrent or metastatic melanoma (MM). (Abstract #9032) Teresa M. Petrella, MD

5 Session Title: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy Location: N Hall B1 Time: 9:45 AM - 12:45 PM Chair and/or Co-Chairs: Deborah Toppmeyer, MD, and Eleanor E. Harris, MD MAC.11-12:15 PM - 12:30 PM S0221: Comparison of two schedules of paclitaxel as adjuvant therapy for breast cancer. (Abstract #CRA1008) G. T. Budd, MD Session Title: Health Services Research Time: 1:15 PM - 5:00 PM MAP.3 - Poster Board: #13E NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic minority women taking the aromatase inhibitor (AI) exemestane (EXE) for breast cancer risk reduction. (Abstract #6557) Beverly Moy, MD Session Title: Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy Location: S102 Time: 1:15 PM - 5:15 PM Chair and/or Co-Chairs: Melinda L. Telli, MD, and Janice M. Walshe, MD MA.32 - Poster Board: #25 Effect of metformin versus placebo on weight and metabolic factors in initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant randomized controlled trial in early-stage breast cancer (BC). (Abstract #1033) Pamela J. Goodwin, MD, MSc

6 Tuesday, June 4 Session Title: Gastrointestinal (Colorectal) Cancer Date: Tue, Jun 4 Location: S405 Time: 8:00 AM - 12:00 PM Chair and/or Co-Chairs: Nancy N. Baxter, MD, PhD, FRCS, and Sharlene Gill, MD, MPH CO.17 - Poster Board: #20 Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17. (Abstract #3528) Stephanie Y. Brule, MD